Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05607004
Recruiting
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. The PK part (how the body processes the drug) will enroll about 18 participants. All participants will take (Z)-endoxifen capsules dail... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114
Recruiting
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Mercy Clinic Oncology and Hematology - Joplin, Joplin, Missouri
Conditions: Non-Small Cell Lung Cancer
Register for Updates
PET Detection of CCR2 in Human Atherosclerosis
NCT04537403
Recruiting
: Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/28/2025
Locations: Washington University CCIR, Saint Louis, Missouri
Conditions: Carotid Atherosclerosis
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
07/28/2025
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
NCT02812290
Recruiting
Objective: To evaluate the potential impact of molecular phenotyping of transbronchial biopsies in lung transplant recipients with allograft dysfunction, and the potential for developing a safer endobronchial mucosal biopsy format.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Division of Pulmonary and Critical Care, Washington University School of Medicine, Saint Louis, Missouri
Conditions: Lung Transplant Rejection
Register for Updates
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study
NCT07000734
Recruiting
The purpose of this research study is to explore ways to improve motor, cognitive and immune functions for aging adults using multiple techniques like lifestyle changes and risk factor management, as well as medications and supplements believed to have a positive effect on health.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
07/25/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Aging, Cognitive Decline, Older Adults, Cardiovascular, Sedentary Behaviors, Immune Senescence, Motor Function
Register for Updates
Clinical Course Of Disease In Participants With FA-CM
NCT06865482
Recruiting
Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)
Gender:
ALL
Ages:
6 years and above
Trial Updated:
07/25/2025
Locations: Washington University School of Medicine in St. Louis, St. Louis, Missouri
Conditions: Friedreich Ataxia, Cardiomyopathy
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Bridgeton, Missouri
Conditions: Non-small Cell Lung Cancer
Register for Updates
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
NCT05287451
Recruiting
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Ovarian Cancer, Fallopian Tube Cancer
Register for Updates
The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
NCT04494295
Recruiting
This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: University of Missouri, Columbia, Missouri
Conditions: Supratentorial Hemorrhage
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2025
Locations: RANGER & MATCH: University of Missouri - Columbia, Columbia, Missouri
Conditions: Peripheral Nerve Injuries
Register for Updates
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868
Recruiting
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Local Institution - 0284, Kansas City, Missouri
Conditions: Breast Neoplasms
Register for Updates